Belite Bio (BLTE)
(Delayed Data from NSDQ)
$48.68 USD
+0.22 (0.45%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $47.65 -1.03 (-2.12%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.68 USD
+0.22 (0.45%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $47.65 -1.03 (-2.12%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum D VGM
Zacks News
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why
by Zacks Equity Research
Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.